Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 16/20 | 0.55 |
| ▸ | ITK | Q08881 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2066323 | 1.00 | NTRK1 (0.55) | NTRK1ITKKDRROCK2ROCK1 | |
| SCHEMBL2066329 | 0.90 | NTRK1 (0.53) | NTRK1ITKKDR | |
| SCHEMBL2066328 | 0.90 | NTRK1 (0.53) | NTRK1ITKKDR | |
| SCHEMBL14460913 | 0.88 | NTRK1 (0.72) | NTRK1ITK | |
| SCHEMBL2066674 | 0.81 | NTRK1 (0.59) | NTRK1ITKKDR | |
| SCHEMBL2064842 | 0.80 | NTRK1 (0.58) | NTRK1ITKKDR | |
| SCHEMBL3588019 | 0.80 | NTRK1 (0.54) | NTRK1ITKKDR | |
| SCHEMBL2065362 | 0.78 | NTRK1 (0.52) | NTRK1ITKKDR | |
| SCHEMBL2066041 | 0.78 | NTRK1 (0.63) | NTRK1ITKKDR | |
| SCHEMBL2065681 | 0.76 | NTRK1 (0.54) | NTRK1ITKKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099794-B1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-05-15 | — | — | EP | disclosed |
| US-8148400-B2 | Thiazolyl compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148400-B2 | Thiazolyl compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148400-B2 | Thiazolyl compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-20100048581-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048581-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048581-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048581-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | ERBB2, TEC, TTBK1 | NTRK1 327/4885ITK 82/4885KDR 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.